Marie L. A. Schuttelaar

Author

University Medical Center Groningen ORCID

Also Known As

C Lynde, Gimnez-Arnau, Goossens, M L Schuttelaar, M Schuttelaar, M-L.A. Schuttelaara, M-LA. SCHUTTELAAR, M. L. A. Schuttelaar, M. L. Schuttelaar, M. Schuttelaar

344

Publications

7.9K

Citations

H-Index

113

Concepts

All Affiliations

University Medical Center Groningen University of Groningen University Medical Center Utrecht Friedrich-Alexander-Universität Erlangen-Nürnberg Heidelberg University

About

Marie L. A. Schuttelaar is an author at University Medical Center Groningen specializing in dermatology, medicine, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	31	980
2	Public Health	8	8	227
3	Arts	2	2	68
4	Engineering	1	1	52
5	Health Sciences	1	1	15

Marie L. A. Schuttelaar

149

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study Mette Deleuran, Diamant Thaçi, Lisa A. Beck, Journal of the American Academy of Dermatology	2019	248
Guidelines for diagnosis, prevention, and treatment of hand eczema Jacob P. Thyssen, Marie L. A. Schuttelaar, José Hernán Alfonso, Contact Dermatitis	2021	228
Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting Jochen Schmitt, Phyllis I. Spuls, Maarten Boers, Allergy	2012	187
Proactive disease management with 0·03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study Diamant Thaçi, Sakari Reitamo, María Antonia González Enseñat, British Journal of Dermatology	2008	179
The European baseline series in 10 European Countries, 2005/2006 – Results of the European Surveillance System on Contact Allergies (ESSCA) Wolfgang Uter, C. Rämsch, Werner Aberer, Contact Dermatitis	2009	179
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Joanne R Chalmers, Kim S Thomas, Christian Apfelbacher, British Journal of Dermatology	2018	160
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker, Allergy	2019	146
Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial Bárður Sigurgeirsson, Andrzej Boznański, Gail Todd, PEDIATRICS	2015	145
Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure Marie L. A. Schuttelaar, Marjan Kerkhof, Marcel F. Jonkman, Allergy	2009	136
Current patch test results with the European baseline series and extensions to it from the ‘European Surveillance System on Contact Allergy’ network, 2007–2008 Wolfgang Uter, Werner Aberer, J.C. Armario-Hita, Contact Dermatitis	2012	133

Page 1